UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012752
Receipt number R000014867
Scientific Title A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen
Date of disclosure of the study information 2014/01/06
Last modified on 2020/12/02 08:21:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen

Acronym

NECTOR

Scientific Title

A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen

Scientific Title:Acronym

NECTOR

Region

Japan


Condition

Condition

Unresectable pancreatic neuroendocrine carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Progression free survival

Key secondary outcomes

Overall survival, time to treatment failure, response rate, disease control rate, adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Everolimus 10mg once daily

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Pathologically confirmed pancreatic neuroendocrine carcinoma
2) No indication for surgical resection
3) 20 years of age or over
4) ECOG performance status 0-2
5) Refractory or intolerant to platinum-based regimen
6) Having evaluable lesion by CT
7) No previous chemotherapy within 3 weeks
8) Adequate organ function
9) Written informed consent

Key exclusion criteria

1) NET G1 or G2 by WHO 2010 criteria
2) Interstitial pneumonia or plumonary fibrosis
3) Metastasis to the central nervous system
4) Concomitant malignancy within 3 years
5) Active infection (exept for hepatitis B or C viral infection)
6) Active gastrointestinal ulcer
7) Severe or uncontrollable complications, such as cardiovascular impairment, infection, diabetes mellitus, and pulmonary disease
8) Severe mental disorder
9) Continuous administration of steroid or immunosuppressant
10) Prior treatment of mTOR inhibitor
11) Pregnant or lactating women and women of childbearing age who were not using effective contraception
12) Patients who was judged to be inappropriate for this study by each investigators

Target sample size

25


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masafumi Ikeda

Organization

National Cancer Center Hospital East

Division name

Department of Hepatobiliary and Pancreatic Oncology

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, JAPAN

TEL

+81-4-7133-1111

Email

masikeda@east.ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroyuki Okuyama

Organization

National Cancer Center Hospital East

Division name

Department of Hepatobiliary and Pancreatic Oncology

Zip code


Address

6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, JAPAN

TEL

+81-4-7133-1111

Homepage URL


Email

hokuyama@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital East

Institute

Department

Personal name



Funding Source

Organization

Cancer Fundation

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

愛知県がんセンター中央病院(愛知県),石川県立中央病院(石川県),大阪府立成人病センター(大阪府),岡山大学(岡山県),香川大学(香川県),神奈川県立がんセンター(神奈川県),金沢大学(石川県),がん研究会有明病院(東京都),関西医科大学(大阪府),北里大学東病院(神奈川県),九州大学(福岡県),京都府立医科大学(京都府),杏林大学(東京都),神戸大学(兵庫県),国立がん研究センター中央病院(東京都),国立がん研究センター東病院(千葉県),国立国際医療研究センター(東京都),大阪医療センター(大阪府),九州がんセンター(福岡県),四国がんセンター(愛媛県),埼玉県立がんセンター(埼玉県),札幌医科大学(北海道),静岡県立静岡がんセンター(静岡県),自治医科大学(栃木県),千葉大学(千葉県),手稲渓仁会病院(北海道),東海大学(神奈川県),東京慈恵会医科大学(東京都),東京慈恵会医科大学附属柏病院(千葉県),東京大学(東京都),富山大学(富山県),名古屋市立西部医療センター(愛知県),宮崎大学(宮崎県),横浜市立大学附属市民総合医療センター(神奈川県)


Other administrative information

Date of disclosure of the study information

2014 Year 01 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 12 Month 26 Day

Date of IRB

2013 Year 12 Month 04 Day

Anticipated trial start date

2014 Year 01 Month 06 Day

Last follow-up date

2019 Year 01 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 01 Month 04 Day

Last modified on

2020 Year 12 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014867


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name